Table 2.
Cell | Compartment | Approximate abundance | Comment | Reference |
---|---|---|---|---|
CD8+ | T1 Dec | 70% of CD3+ | Reversed CD4/8 versus PB | [61, 96] |
Term Dec basalis/parietalis | Virus-specific viral control | [98] | ||
Term Dec basalis/parietalis | ↓ perforin versus PB | [100] | ||
Term PB | Hyporesponsiveness | [106] | ||
Term DSC | Hyporesponsiveness | [103] | ||
| ||||
CD4+ | T1 Dec | 20% of CD3+ | [61] | |
Th1 | T1 Dec | 15% of CD4+ | CCR4−CXCR3+CCR6− | [110] |
T1, T2, T3, PP PB | 112, 110, 156, 53/100000 lymph | IFN-γ secreting cells | [115] | |
T1 → T3 PB | 20 → 17% of CD4+ | IFN-γ+ ICS | [114] | |
T1 → T3 PB | 1% lower CD4+CD45RA+ | IFN-γ+ ICS, Rel free versus Rel MS PP | [125] | |
Th2 | T1 Dec | 5% of CD4+ | CCR4+CXCR3−CCR6− | [110] |
T1, T2, T3, PP PB | 84, 87, 119, 54/100000 lymph | IL-4 secreting cells | [115] | |
T1→ T3 PB | 2.3 → 3% of CD4+ | IL-4 ICS | [114] | |
T3 PB | 3% versus 1.5% of CD4+ | No PE versus PE | [114] | |
Th17 | T1 Dec | 1-2% of CD4+ | CCR4+CXCR3+CCR6+, IL17+ ICS | [110] [138] |
T1 → T3 PB | 1-2% of CD4+ | IL-17+ ICS | [138] | |
Preterm amniotic fluid, decidua | Il-17+ ICS Th17 Inflammation in hAMSC | [152] | ||
T1 PB | ↑ IL-17/CCR6+ in spontaneous abortion | [150] | ||
Treg | T1 Dec | 2% of CD4+ | CD25highFOXP3high | [110] |
Term Dec, PB | Dec ↑ CTLA-4+, HLA-DR+, CD69+ versus PB | [123] | ||
T1, T2, T3 PB | 6.7, 10.9, 8.9% of CD4+ | CD4+CD25+ | [171] | |
T2 PB | 6 versus 7.5% of CD4+ | FOXP3+ pregnant versus nonpregnant. Reduced by hormones | [178] | |
Term DSC | ↑ Tregs, partly by IDO | [120] |
CD: cluster of differentiation; Dec: decidua; DSC: decidual stromal cells; hAMSC: human amniotic mesenchymal stromal cells; ICS: intracellular staining; IDO: indoleamine-2,3-dieoxygenase; lymph: lymphocytes; PB: peripheral blood; PE: preeclampsia; PP: postpartum; MS: multiple sclerosis; Rel: relapse; Treg: regulatory T cells; T1–3: trimester 1–3; TLR: toll-like receptor; UC: umbilical cord.